gdc
PSSGuide_2021

Drugs for Solid Tumors with NTRK Gene Fusion

Here are the drugs and financial support services available to patients receiving treatment for Solid Tumors with NTRK Gene Fusion.

Drugs for Solid Tumors with NTRK Gene Fusion

Rozlytrek (entrectinib)

Drug company: Genentech
866-422-2377

Rozlytrek is a kinase inhibitor used for the treatment of patients age 12 or older with solid tumors that are associated with a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are metastatic or are not candidates for surgery, or have progressed after treatment or they have no alternative therapy.

Genentech Oncology offers 2 financial assistance programs for patients who have been prescribed Rozlytrek:

Genentech Oncology Co-pay Assistance Program

Patients who have private insurance will pay a $5 copay per prescription of Rozlytrek, with a benefit limit of $25,000 per year. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Rozlytrek free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For households with more than 4 people, add $25,000 per each additional member. Rozlytrek is also provided free for patients who are unable to afford their outof- pocket costs and cannot find other financial assistance.

Vitrakvi (larotrectinib)

Drug company: Bayer
844-634-8725

Vitrakvi is a kinase inhibitor used for the treatment of all patients with solid tumors that are associated with a neurotrophic tyrosine receptor kinase (NTRK) gene fusion and have no known acquired resistance mutation, are metastatic or are not candidates for surgery, or have no alternative treatments or have progressed after treatment.

Bayer offers 4 financial assistance programs for patients who have been prescribed Vitrakvi:

TRAK Assist $0 Copay Program

Through this program, patients who have commercial or private insurance may qualify for $0 copay for Vitrakvi. Patients enrolled in any type of government insurance or reimbursement programs are not eligible for the $0 copay program.

Vitrakvi Bridge Program

This program provides free Vitrakvi for a limited time for patients with private insurance who experience delayed insurance coverage or a temporary lapse in coverage.

Vitrakvi Commitment Program

Eligible patients who do not experience clinical benefit within 90 days of beginning Vitrakvi therapy may receive full or partial refunds of the cost of the drug (for up to 60 days). This program is for patients who are enrolled in private insurance plans, Medicare Part D, Medicaid, other government insurance, or who are responsible for the full cost of Vitrakvi. To qualify for this program, patients must receive Vitrakvi through a Vitrakvi In-Network Specialty Pharmacy.

Bayer US Patient Assistance Foundation

This foundation provides Vitrakvi free of charge to uninsured or underinsured patients who meet specific financial criteria.

Table. Drugs Prescribed for Solid Tumors with NTRK Gene Fusion

  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services
    Drug name (generic name)
  • Rozlytrek (entrectinib)
  • Drug company
  • Genentech
  • Indication
  • Treatment of patients 12 or older with solid tumors and an NTRK gene fusion, are metastatic or are not candidates for surgery, or have progressed after treatment or they have no alternative therapy
  • Patient support services
  • Genentech Oncology Co-pay Assistance Program
    855-692-6729

    Genentech Patient Foundation
    888-941-3331


Share this:

Last modified: April 8, 2021

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country